Engineering of Saccharomyces pastorianus Old Yellow Enzyme 1 for the Synthesis of Pharmacologically Active (S)-Profen Derivatives
<a>2-Arylpropionic acid </a><a>derivatives</a>, such as ibuprofen, constitute an important group of non-steroidal anti-inflammatory drugs (NSAIDs). Biocatalytic asymmetric reduction of<a> 2-arylacrylic acid</a> derivatives by ene reductases (EREDs) is a valuable approach for synthesis of these derivatives. However, previous bioreduction of <a>2-arylacrylic acid derivatives</a> by either ERED wild-types or variants resulted solely in nonpharmacological (<i>R</i>)-enantiomers as the products. <a></a><a>Here, </a>we present the engineering of <i>Saccharomyces pastorianus</i> old yellow enzyme 1 (OYE1) into (<i>S</i>)-stereoselective enzymes, which afford pharmacologically active (<i>S</i>)-profen derivatives. By structural comparison of substrate recognition in related EREDs and analysis of non-covalent contacts in the pro-<i>S</i> model of OYE1, the key residues of OYE1 that switch its stereoselectivity to an (<i>S</i>)-stereopreference were identified. Systematic site-directed mutagenesis screening at these positions successfully provided the (<i>S</i>)-stereoselective OYE1 variants, which catalyzed stereoselective bioreduction of various profen precursors to afford pharmacologically active (<i>S</i>)-derivatives including (<i>S</i>)-ibuprofen and (<i>S</i>)-naproxen methyl esters with up to >99% <i>ee</i> values. <a>Moreover, the key residues and mutation strategy obtained from OYE1 </a>could be further transferred to OYE 2.6 (from <i>Pichia stipitis</i>) and KnOYE1 (from <i>Kazachstania naganishii</i>) to create the (<i>S</i>)-stereoselective EREDs. Our results may provide a generalizable strategy for stereocontrol of OYEs and set the basis for biocatalytic production of (<i>S</i>)-profens.